MARKET

SLDB

SLDB

SOLID BIOSCIENCE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.110
+0.090
+4.46%
Closed 16:00 09/25 EDT
OPEN
2.040
PREV CLOSE
2.020
HIGH
2.130
LOW
2.020
VOLUME
143.47K
TURNOVER
--
52 WEEK HIGH
13.58
52 WEEK LOW
1.930
MARKET CAP
97.27M
P/E (TTM)
-0.9227
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 2d ago
FDA Delays Start of Sareptas Gene Therapy Trial. That Doesnt Faze the Stocks Bulls.
The delay will cost the company a few months at most, analysts say.
Barrons.com · 09/10 15:19
Radius Health Licensing Deal, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 07/28 18:34
FDA Again Keeps Solid Biosciences’ Duchenne Trial On Clinical Hold
Solid Biosciences (SLDB) has announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the company’s IGNITE DMD Phase I/II clinical trial remains on clinical hold.In November 2019, the FDA placed IGNITE DMD on clinical hold as the
TipRanks · 07/27 16:16
FDA maintains clinical hold on Solid Bio's Ignite DMD trial
Seeking Alpha · 07/27 09:42
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced that it received written communication from the U.S. F
GlobeNewswire · 07/24 21:50
Solid Biosciences Inc. (SLDB): Hedge Fund Sentiment Unchanged
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 07/05 21:27
How R&D Expenses Can Help You Pick Outperforming Stocks
Seeking Alpha - Article · 07/02 16:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLDB. Analyze the recent business situations of SOLID BIOSCIENCE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLDB stock price target is 3.000 with a high estimate of 5.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 113
Institutional Holdings: 29.73M
% Owned: 64.48%
Shares Outstanding: 46.10M
TypeInstitutionsShares
Increased
22
1.24M
New
26
-35.22K
Decreased
21
812.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Director
Ian Smith
President/Chief Executive Officer/Co-Founder/Director
Ilan Ganot
Chief Financial Officer/Treasurer
Jennifer Ziolkowski
Chief Technology Officer
Joel Schneider
Chief Scientific Officer
Carl Morris
Secretary
Lynette Herscha
Independent Director
Matthew Arnold
Independent Director
Martin Freed
Independent Director
Robert Huffines
Independent Director
Adam Koppel
Independent Director
Sukumar Nagendran
Independent Director
Rajeev Shah
Independent Director
Adam Stone
Independent Director
Lynne Sullivan
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLDB
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Solid Biosciences Inc stock information, including NASDAQ:SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.